|1.01 0.055 (5.75%)||12-01 16:00|
|Targets||6-month :||1.33||1-year :||1.55|
|Resists||First :||1.13||Second :||1.33|
|Supports||First :||0.94||Second :||0.82|
|MAs||MA(5) :||0.96||MA(20) :||0.98|
|MA(100) :||1||MA(250) :||2.12|
|MACD||MACD :||0||Signal :||0|
|%K %D||K(14,3) :||30.7||D(3) :||27.1|
|52-week||High :||6.57||Low :||0.66|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VERU ] has closed below upper band by 34.9%. Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||1.01 - 1.02||1.02 - 1.02|
|Low:||0.91 - 0.92||0.92 - 0.92|
|Close:||1 - 1.01||1.01 - 1.02|
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||90 (M)|
|Shares Float||70 (M)|
|Held by Insiders||22.9 (%)|
|Held by Institutions||36 (%)|
|Shares Short||14,270 (K)|
|Shares Short P.Month||13,190 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0.23|
|Profit Margin||0 %|
|Operating Margin||-377.1 %|
|Return on Assets (ttm)||-72.1 %|
|Return on Equity (ttm)||-178.4 %|
|Qtrly Rev. Growth||-65.2 %|
|Gross Profit (p.s.)||0.33|
|Sales Per Share||0.16|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-99 (M)|
|Levered Free Cash Flow||-54 (M)|
|Price to Book value||4.2|
|Price to Sales||6.07|
|Price to Cash Flow||-0.92|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|